ENDRA Life Sciences (NDRA) EBITDA Margin (2016 - 2018)
Historic EBITDA Margin for ENDRA Life Sciences (NDRA) over the last 3 years, with Q1 2018 value amounting to 45960.77%.
- ENDRA Life Sciences' EBITDA Margin changed N/A to 45960.77% in Q1 2018 from the same period last year, while for Dec 2018 it was 146080.47%, marking a year-over-year decrease of 1447651200.0%. This contributed to the annual value of 9971.19% for FY2024, which is 76864800.0% down from last year.
- Per ENDRA Life Sciences' latest filing, its EBITDA Margin stood at 45960.77% for Q1 2018.
- ENDRA Life Sciences' EBITDA Margin's 5-year high stood at 210.52% during Q2 2016, with a 5-year trough of 45960.77% in Q1 2018.
- Over the past 3 years, ENDRA Life Sciences' median EBITDA Margin value was 1073.38% (recorded in 2017), while the average stood at 13580.91%.
- Data for ENDRA Life Sciences' EBITDA Margin shows a peak YoY increase of -20398800bps (in 2017) and a maximum YoY decrease of -334647400bps (in 2017) over the last 5 years.
- ENDRA Life Sciences' EBITDA Margin (Quarter) stood at 61.85% in 2016, then plummeted by -54107bps to 33526.58% in 2017, then tumbled by -37bps to 45960.77% in 2018.
- Its last three reported values are 45960.77% in Q1 2018, 33526.58% for Q4 2017, and 317.4% during Q3 2017.